Explore our decade-long journey and research collaboration with international experts. In this infographic, we highlight the potentially transformative impact of our AI-driven Precision Pathology solution on HER2-targeted treatment strategies for breast- and gastric cancer patients. This IVDR-cleared methodology is currently used in clinical practice for decision support when reading HER2-IHC assays. It enhances diagnostic accuracy, is optimized for concordance with HER2-FISH, significantly reduces the need for reflex testing, and has been shown to identify responders to anti-HER2 neoadjuvant chemotherapy.
We will soon release a whitepaper on this subject, which you can sign up to receive by submitting your email further down this page.
Whitepaper sign up
Share your email to get notified when the whitepaper is published.Visiopharm Categories: Blog